Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, TG Therapeutics Inc’s stock clocked out at $37.42, down -1.29% from its previous closing price of $37.91. In other words, the price has decreased by -$1.29 from its previous closing price. On the day, 1.12 million shares were traded. TGTX stock price reached its highest trading level at $38.15 during the session, while it also had its lowest trading level at $37.16.
Ratios:
To gain a deeper understanding of TGTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 4.02. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 1.06.
On October 29, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $50.
Goldman Upgraded its Sell to Neutral on August 02, 2023, whereas the target price for the stock was revised from $16 to $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Echelard Yann sold 10,000 shares for $36.94 per share. The transaction valued at 369,400 led to the insider holds 228,816 shares of the business.
Echelard Yann bought 10,000 shares of TGTX for $369,348 on Jun 13 ’25. On Jan 03 ’25, another insider, Power Sean A, who serves as the CFO of the company, sold 11,337 shares for $30.29 each. As a result, the insider received 343,443 and left with 670,632 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5940612096 and an Enterprise Value of 5226260480. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 153.36, and their Forward P/E ratio for the next fiscal year is 21.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.37 while its Price-to-Book (P/B) ratio in mrq is 24.94. Its current Enterprise Value per Revenue stands at 13.526 whereas that against EBITDA is 87.296.
Stock Price History:
The Beta on a monthly basis for TGTX is 1.95, which has changed by 0.85469663 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $16.65. The 50-Day Moving Average of the stock is 2.92%, while the 200-Day Moving Average is calculated to be 11.92%.
Shares Statistics:
It appears that TGTX traded 2.13M shares on average per day over the past three months and 1582710 shares per day over the past ten days. A total of 158.17M shares are outstanding, with a floating share count of 142.98M. Insiders hold about 9.93% of the company’s shares, while institutions hold 62.38% stake in the company. Shares short for TGTX as of 1749772800 were 23697171 with a Short Ratio of 11.29, compared to 1747267200 on 22571826. Therefore, it implies a Short% of Shares Outstanding of 23697171 and a Short% of Float of 19.520001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.27, with high estimates of $0.4 and low estimates of $0.15.
Analysts are recommending an EPS of between $1.33 and $0.58 for the fiscal current year, implying an average EPS of $0.95. EPS for the following year is $1.8, with 5.0 analysts recommending between $2.52 and $1.04.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $147.76M. It ranges from a high estimate of $192.05M to a low estimate of $136.4M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $73.47MFor the next quarter, 6 analysts are estimating revenue of $153.05M. There is a high estimate of $162M for the next quarter, whereas the lowest estimate is $148M.
A total of 6 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $633.4M, while the lowest revenue estimate was $574.51M, resulting in an average revenue estimate of $596.09M. In the same quarter a year ago, actual revenue was $329MBased on 6 analysts’ estimates, the company’s revenue will be $824.6M in the next fiscal year. The high estimate is $893.8M and the low estimate is $692.6M.
